The Latest Cardiac and Vascular News
– Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. – BD’s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. – BD’s core growth led by strong growth in Medication Delivery Solutions […]
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, […]
WEST CONSHOHOCKEN, Pa., May 06, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. “We expect several important events for Madrigal to occur in 2021,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “These include completing enrolling a sufficient number […]
SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (NASDAQ: OTRKP) (“Ontrak” or the “Company”) today announced that its Board of Directors has declared the third quarterly cash dividend for the Company’s 9.50% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”). The third quarterly cash dividend equals $0.593750 per share, at […]
SUNNYVALE, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended March 31, 2021. “Our first quarter results were characterized by meaningful progress on several commercial […]
Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 SILVER SPRING, […]
On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights. “In the first quarter, we took important steps to maximize […]
ANDOVER, Mass., May 4, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2021. Recent Highlights Net revenue of $7.1 million in the first quarter of 2021, […]
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets – – Secured Major Medicare Part D Contract Covering Approximately 8.5 Million Lives – – […]
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company […]
